Dual-time-point FDG PET/CT for the evaluation of pediatric tumors

American Journal of Roentgenology

Volumn 200, Issue 2, 2013, Pages 408-413

  Costantini, Danny L ^a,b   Vali, Reza ^b   Chan, Jeffery ^b   McQuattie, Susan ^b   Charron, Martin ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Dual time point PET; Oncology; Pediatric; PET CT

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADOLESCENT; ANALYTICAL PARAMETERS; ARTICLE; BENIGN TUMOR; BURKITT LYMPHOMA; CANCER OF UNKNOWN PRIMARY SITE; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HODGKIN DISEASE; HUMAN; INFANT; LARGE CELL LYMPHOMA; MALE; MALIGNANT NEOPLASTIC DISEASE; NEUROBLASTOMA; ONCOLOGICAL PARAMETERS; PATIENT ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; RETENTION INDEX; RHABDOMYOSARCOMA; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; STANDARDIZED UPTAKE VALUE; THYROID PAPILLARY CARCINOMA; TUMOR DIFFERENTIATION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; INFANT; MALE; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY;

EID: 84873585399     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.12.8930     Document Type: Article

References (24)

1. Shammas A, Lim R, Charron M. Pediatric FDG PET/CT: physiologic uptake, normal variants, and benign conditions. RadioGraphics 2009; 29:1467-1486
2. Charron M. Practical pediatric PET imaging. New York, NY: Springer-Verlag Science+Business Media, 2006
3. Alkhawaldeh K, Bural G, Kumar R, Alavi A. Impact of dual-time-point (18)F-FDG PET imaging and partial volume correction in the assessment of solitary pulmonary nodules. Eur J Nucl Med Mol Imaging 2008; 35:246-252
4. Buck A, Schirrmeister H, Kuhn T, et al. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging 2002; 29:1317-1323
5. Hamberg LM, Hunter GJ, Alpert NM, Choi NC, Babich JW, Fischman AJ. The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? J Nucl Med 1994; 35:1308-1312
6. Hustinx R, Smith RJ, Benard F, et al. Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck. Eur J Nucl Med 1999; 26:1345-1348
7. Kumar R, Loving VA, Chauhan A, Zhuang H, Mitchell S, Alavi A. Potential of dual-time-point imaging to improve breast cancer diagnosis with (18)F-FDG PET. J Nucl Med 2005; 46:1819-1824
8. Lodge MA, Lucas JD, Marsden PK, Cronin BF, O'Doherty MJ, Smith MA. A PET study of 18FDG uptake in soft tissue masses. Eur J Nucl Med 1999; 26:22-30
9. Matthies A, Hickeson M, Cuchiara A, Alavi A. Dual time point 18F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med 2002; 43:871-875
10. Zhuang H, Pourdehnad M, Lambright ES, et al. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med 2001; 42:1412-1417
11. Tian R, Su M, Tian Y, et al. Dual-time point PET/CT with F-18 FDG for the differentiation of malignant and benign bone lesions. Skeletal Radiol 2009; 38:451-458
12. Delbeke D, Coleman RE, Guiberteau MJ, et al. Procedure guideline for tumor imaging with 18FFDG PET/CT 1.0. J Nucl Med 2006; 47:885-895
13. Sathiakumar C, Som S, Eberl S, Lin P. NEMA NU 2-2001 performance testing of a Philips Gemini GXL PET/CT scanner. Australas Phys Eng Sci Med 2010; 33:199-209
14. Lan XL, Zhang YX, Wu ZJ, Jia Q, Wei H, Gao ZR. The value of dual time point (18)F-FDG PET imaging for the differentiation between malignant and benign lesions. Clin Radiol 2008; 63:756-764
15. Sanz-Viedma S, Torigian DA, Parsons M, Basu S, Alavi A. Potential clinical utility of dual time point FDG-PET for distinguishing benign from malignant lesions: implications for oncological imaging. Rev Esp Med Nucl 2009; 28:159-166
16. Xiu Y, Bhutani C, Dhurairaj T, et al. Dual-time point FDG PET imaging in the evaluation of pulmonary nodules with minimally increased metabolic activity. Clin Nucl Med 2007; 32:101-105
17. Kazama T, Faria SC, Varavithya V, Phongkitkarun S, Ito H, Macapinlac HA. FDG PET in the evaluation of treatment for lymphoma: clinical usefulness and pitfalls. RadioGraphics 2005; 25:191-207
18. Aoki J, Watanabe H, Shinozaki T, et al. FDG PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions. Radiology 2001; 219:774-777
19. Dimitrakopoulou-Strauss A, Strauss LG, Heichel T, et al. The role of quantitative (18)F-FDG PET studies for the differentiation of malignant and benign bone lesions. J Nucl Med 2002; 43:510-518
20. Kodama H, Murashima S, Takeda K. Role of 18F FDG-PET/CT in pediatric oncology. J Nucl Med 2007; 48(suppl 2):289P
21. Hong TS, Shammas A, Charron M, Zukotynski KA, Drubach LA, Lim R. Brown adipose tissue 18F-FDG uptake in pediatric PET/CT imaging. Pediatr Radiol 2011; 41:759-768
22. Alkhawaldeh K, Alavi A. Quantitative assessment of FDG uptake in brown fat using standardized uptake value and dual-time-point scanning. Clin Nucl Med 2008; 33:663-667
23. Boellaard R, O'Doherty MJ, Weber WA, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 2010; 37:181-200
24. Paidisetty S, Blodgett TM. Brown fat: atypical locations and appearances encountered in PET/CT. AJR 2009; 193:359-366